StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
CHEBullishEarningsnews
High materiality8/10

Chemed Q3 2026: VITAS drives earnings growth while Roto-Rooter margins soften

Oct 27, 2026, 9:19 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Material earnings beat and meaningful VITAS margin expansion imply higher cash flow and potential multiple expansion; but Roto-Rooter margins remain under pressure, creating a balanced risk/reward profile. Historical similar two-segment dynamics often lead to short-term upside with longer-term caveats from margin shifts.

AI summary

What happened, with direct paths to the underlying reporting

Chemed reported solid Q3 2026 results with consolidated revenue of $690.9 million, up 10.6%, and GAAP EPS of $5.45, with adjusted EPS of $6.75, up 28.1%. VITAS Healthcare delivered stronger patient revenue and a margin expansion, while Roto-Rooter posted revenue gains but margin compression, resulting in overall earnings growth.

  • Chemed Q3 2026 revenue up 10.6% to $690.9M; GAAP EPS $5.45.
  • Adjusted EPS up 28.1% to $6.75; VITAS margin up 318 bps.
  • VITAS ADC 24,428; admissions 18,995, up 9.4% and 7.2%.
  • Roto-Rooter revenue up 7.5%; adjusted EBITDA margin down 213 bps to 20.6%.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event